# The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol

> **NCT00283335** · PHASE3 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 2531 (actual)

## Conditions studied

- Coronary Heart Disease

## Interventions

- **DRUG:** gemfibrozil
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00283335
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1991-06
- **Primary completion:** 1998-09
- **Final completion:** 1999-08
- **Target enrollment:** 2531 (ACTUAL)
- **Last updated:** 2015-10-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00283335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00283335, "The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00283335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*